Chenghua Bio Visit | Sincere Collaboration to Build a Bridge for Exchange and Learning in Synthetic Biology

On September 22, 2024, Mr. Ji Limin, Chairman of Shandong Longchang Animal Health Products Co., Ltd. (hereinafter referred to as Lachance Group), along with Vice President Mr. Zhao Xinzhong and Chief Engineer Mr. Ma Wencheng, made a special visit to Sichuan to meet with Dr. Huang Qingdong’s team from Chenghua Bio. The two parties engaged in an in-depth discussion and exchange on synthetic biology.

Chairman Ji and his delegation from Lachance Group took a group photo with Mr. Huang's team from Chenghua Biotechnology

Synthetic biology is at the forefront of today’s biological research. Its development and innovation are expected to have a positive impact on both the economy and society, fundamentally changing existing production processes. Compared to traditional chemical synthesis, synthetic biology offers several advantages, including the use of renewable raw materials, mild reaction conditions, high efficiency, and environmental friendliness. As a result, synthetic biology is gradually replacing traditional chemical synthesis and becoming a key method for "green synthesis" in the global pharmaceutical, food, and materials industries.

With its innovation, cost-effectiveness, high efficiency, sustainability, and broad range of applications, synthetic biology has the potential to revolutionize both the technological and industrial landscapes. It is becoming a driving force for advancing the bioeconomy and promoting sustainable social development.

Chenghua Biotechnology is a high-tech enterprise jointly founded by Academician Chen Xinzi from the Chinese Academy of Sciences, renowned entrepreneur Professor Yang Dengui, and Chengdu specially-appointed expert Dr. Huang Qingdong. It was established in 2019 at the SanYI Innovation Center in Wenjiang District and currently has 40 employees, with over 50% being scientific and technical personnel.

The company mainly focuses on the green process development and industrialization of chiral chemical drug intermediates and active pharmaceutical ingredients (APIs). Key products include ursodeoxycholic acid (UDCA), tauroursodeoxycholic acid (TUDCA), chenodeoxycholic acid (CDCA), obeticholic acid, and other bile acid intermediates and APIs.

Over the past 8 years, Chenghua Biotechnology has consistently adhered to the production of UDCA through synthetic biology and has continuously innovated. After many years, it has gained support and recognition from all sectors, becoming a "pioneer" in the synthetic biology production process within the bile acid industry.

Sichuan Chenghua Bio-technology Co.,Ltd

Chairman Ji Limin of Lachance Group and his delegation

During this visit, we had many reflections. Longchang Animal Health and Chenghua Biotechnology had an in-depth exchange on accelerating mutual understanding and fostering closer learning relationships. Longchang Animal Health also hopes to establish a more reciprocal platform for exchange and learning with Chenghua Biotechnology, leveraging complementary strengths to jointly provide high-quality technical products and systematic solutions for the livestock industry.